On July 21, Ascentage Pharma fell 5.01% in regular trading, trading at HK$34.68/share, with turnover of HK$51.06 million.

On the news front, the company filed a registration statement with the U.S. SEC for a proposed at-the-market offering of up to $200 million in American Depositary Shares. Each ADS represents four ordinary shares. Net proceeds will be used to support the commercialization of olverembatinib and lisaftoclax, ongoing clinical trials, working capital, and general corporate purposes. The proposed offering is subject to Hong Kong Stock Exchange waivers from certain listing rules.

Based on the company's current market capitalization of approximately HK$13.3 billion, the potential new share issuance poses meaningful dilution pressure on existing shareholders. The broader biotechnology sector also showed weakness, with BEIGENE down 1.67%, Akeso down 2.30%, and Innovent Bio down 1.89%, compounding bearish sentiment following a sector-wide pullback on July 17.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)